Palafox M, Monserrat L, Bellet M, Villacampa G, González-Pérez A, Oliveira M, Brasó F, Ibrahimi N, Kannan S, Mina L, Herrera-Abreu MT, Odena A, Sanchez-Guixe M, Capelan M, Azaro A, Bruna A, Rodríguez O, Guzman M, Grueso J, Viaplana C, Hernandez J, Su F, Lin K, Clarke RB, Caldas C, Arribas J, Michiels S, Garcia-Sanz A, Turner NC, Prat A, Nuciforo P, Dienstmann R, Verma CS, López-Bigas N, Scaltriti M, Arnedos M, Saura C, Serra V
*.
High p16 expression and heterozygous RB1 loss are biomarkers for CDK4/6 inhibitor resistance in ER + breast cancer. Nat Commun 2022; 13(1): 5258.